INTRODUCTION: Mood and anxiety disorders are comorbid with migraine and commonly assumed to portend a poor response to preventive migraine therapies. However, there is little evidence to support this assumption. METHOD: We examined impact of a mood and/or anxiety disorder diagnosis using American Psychiatric Association Diagnostic and Statistical Manual criteria on response to the three preventative migraine therapies evaluated in the Treatment of Severe Migraine trial (n = 177): β-blocker, behavioral migraine management, or behavioral migraine management +β-blocker. Daily diaries assessed migraine activity for the 16 months of the trial. The Migraine Specific Quality of Life Questionnaire and Headache Disability Inventory assessed headache-related disability at regular intervals. Mixed models for repeated measures examined changes in these three outcomes with preventative migraine therapy in participants with and without a mood or anxiety disorder diagnosis. RESULTS:Participants with a comorbid mood or anxiety disorder diagnosis recorded larger reductions in migraine days (p < .05) and larger reductions in the Migraine Specific Quality of Life Questionnaire (p < .001) and Headache Disability Inventory (p < .01) than did participants with neither diagnosis. DISCUSSION: Significantly larger reductions in migraine activity and migraine-related disability were observed in participants with a mood and/or anxiety disorder diagnosis than in participants who did not receive either diagnosis.
RCT Entities:
INTRODUCTION: Mood and anxiety disorders are comorbid with migraine and commonly assumed to portend a poor response to preventive migraine therapies. However, there is little evidence to support this assumption. METHOD: We examined impact of a mood and/or anxiety disorder diagnosis using American Psychiatric Association Diagnostic and Statistical Manual criteria on response to the three preventative migraine therapies evaluated in the Treatment of Severe Migraine trial (n = 177): β-blocker, behavioral migraine management, or behavioral migraine management +β-blocker. Daily diaries assessed migraine activity for the 16 months of the trial. The Migraine Specific Quality of Life Questionnaire and Headache Disability Inventory assessed headache-related disability at regular intervals. Mixed models for repeated measures examined changes in these three outcomes with preventative migraine therapy in participants with and without a mood or anxiety disorder diagnosis. RESULTS:Participants with a comorbid mood or anxiety disorder diagnosis recorded larger reductions in migraine days (p < .05) and larger reductions in the Migraine Specific Quality of Life Questionnaire (p < .001) and Headache Disability Inventory (p < .01) than did participants with neither diagnosis. DISCUSSION: Significantly larger reductions in migraine activity and migraine-related disability were observed in participants with a mood and/or anxiety disorder diagnosis than in participants who did not receive either diagnosis.
Authors: Elizabeth K Seng; Dawn C Buse; Jaclyn E Klepper; Sarah J Mayson; Amy S Grinberg; Brian M Grosberg; Jelena M Pavlovic; Matthew S Robbins; Sarah E Vollbracht; Richard B Lipton Journal: Headache Date: 2017-01-31 Impact factor: 5.887
Authors: Laura Campbell-Sills; Murray B Stein; Cathy D Sherbourne; Michelle G Craske; Greer Sullivan; Daniela Golinelli; Ariel J Lang; Denise A Chavira; Alexander Bystritsky; Raphael D Rose; Stacy Shaw Welch; Gene A Kallenberg; Peter Roy-Byrne Journal: Psychosom Med Date: 2013-07-25 Impact factor: 4.312
Authors: Mia T Minen; Sarah Corner; Thomas Berk; Valeriya Levitan; Steven Friedman; Samrachana Adhikari; Elizabeth B Seng Journal: Gen Hosp Psychiatry Date: 2021-01-07 Impact factor: 3.238